Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma

Clinical Cancer Research

Volumn 12, Issue 7 I, 2006, Pages 2070-2079

  Mendrzyk, Frank ^a   Korshunov, Andrey ^c   Benner, Axel ^a   Toedt, Grischa ^a   Pfister, Stefan ^a,b   Radlwimmer, Bernhard ^a   Lichter, Peter ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c BURDENKO NEUROSURGICAL INSTITUTE   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA;

ADOLESCENT; ADULT; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CHILD; CHROMOSOME 1Q; CHROMOSOME 5P; CHROMOSOME 7P; CHROMOSOME ABERRATION; CHROMOSOME IDENTIFICATION; CHROMOSOME MAP; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA MICROARRAY; EPENDYMOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENOMIC FRAGMENT; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR RECURRENCE;

ADOLESCENT; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; DNA; EPENDYMOMA; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MULTIVARIATE ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33646262611     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2363     Document Type: Article

References (49)

1. McLendon RE, Enterline DS, Tien RD, Thorstad WL, Bruner JM. Tumors of central epithelial origin. In: Bigner DD, McLendon RE, Bruner JM, editors. Russel and Rubunstein's pathology of tumors of the nervous system. London: Arnold; 1998. p. 387-418.
2. Wiestler OD, Schiffer D, Coons SW, Prayson RA, Rosenblum MK. Ependymal tumors. In: Kleihues P, Cavenee WK, editors. Pathology and genetics of tumours of the nervous system. Lyons: IARC Press; 2000. p. 71-8.
3. Hamilton RL, Pollack IF. The molecular biology of ependymomas. Brain Pathol 1997;7:807-22.
4. Teo C, Nakaji P, Symons P, Tobias V, Cohn R, Smee R. Ependymoma. Childs Nerv Syst 2003;19:270-85.
5. McLaughlin MP, Marcus RB, Buatti JM, et al. Ependymoma: results, prognostic factors and treatment recommendations. Int J Radiat Oncol Biol Phys 1998;40:845-50.
6. Asazuma T, Toyama Y, Suzuki IM, Fujimura Y, Hirabayshi K. Ependymomas of the spinal cord and cauda equina: an analysis of 26 cases and a review of the literature. Spinal Cord 1999;37:753-9.
7. Pollack IF, Gerszten PC, Martinez AJ, et al. Intracranial ependymomas of childhood: long-term outcome and prognostic factors. Neurosurgery 1995;37:655-66; discussion 66-7.
8. Robertson PL, Zeltzer PM, Boyett JM, et al. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. J Neurosurg 1998;88:695-703.
9. Hirose Y, Aldape K, Bollen A, et al. Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol 2001;158:1137-43.
10. Dyer S, Prebble E, Davison V, et al. Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups. Am J Pathol 2002;161:2133-41.
11. Jeuken JW, Sprenger SH, Gilhuis J, Teepen HL, Grotenhuis AJ, Wesseling P. Correlation between localization, age, and chromosomal imbalances in ependymal tumours as detected by CGH. J Pathol 2002;197:238-44.
12. Carter M, Nicholson J, Ross F, et al. Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer 2002;86:929-39.
13. Korshunov A, Neben K, Wrobel G, et al. Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. Am J Pathol 2003;163:1721-7.
14. Ward S, Harding B, Wilkins P, et al. Gain of 1q and loss of 22 are the most common changes detected by comparative genomic hybridisation in paediatric ependymoma. Genes Chromosomes Cancer 2001;32:59-66.
15. Mazewski C, Soukup S, Ballard E, Gotwals B, Lampkin B. Karyotype studies in 18 ependymomas with literature review of 107 cases. Cancer Genet Cytogenet 1999;113:1-8.
16. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994;52:450-61.
17. Ebert C, von Haken M, Meyer-Puttlitz B, et al. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol 1999;155:627-32.
18. Lamszus K, Lachenmayer L, Heinemann U, et al. Molecular genetic alterations on chromosomes 11 and 22 in ependymomas. Int J Cancer 2001;91:803-8.
19. Suarez-Merino B, Hubank M, Revesz T, et al. Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. Neuro-oncol 2005;7:20-31.
20. Solinas-Toldo S, Lampel S, Stilgenbauer S, et al. Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer 1997;20:399-407.
21. Zielinski B, Gratias S, Toedt G, et al. Detection of chromosomal imbalances in retinoblastoma by matrix-based comparative genomic hybridization. Genes Chromosomes Cancer 2005;43:294-301.
22. Mendrzyk F, Radlwimmer B, Joos S, et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 2005;23:8853-62.
23. Stange DE, Radlwimmer B, Schubert F, et al. High resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histological and genetic subgroups of invasive breast cancer. Clin Cancer Res 2006;12:345-52.
24. Mendrzyk F, Korshunov A, Toedt G, et al. The isochromosome breakpoints on 17p in medulloblastoma are flanked by different classes of DNA sequence repeats. Genes Chromosomes Cancer 2006;45:401-10.
25. Merchant TE, Jenkins JJ, Burger PC, et al. Influence of tumor grade on time to progression after irradiation for localized ependymoma in children. Int J Radiat Oncol Biol Phys 2002;53:52-7.
26. Korshunov A, Golanov A, Sycheva R, Timirgaz V. The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients. Cancer 2004;100:1230-7.
27. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med 1986;5:255-60.
28. Fiegler H, Carr P, Douglas EJ, et al. DNA microarrays for comparative genomic hybridization based on DOP-PCR amplification of BAC and PAC clones. Genes Chromosomes Cancer 2003;36:361-74.
29. Knight SJ, Lese CM, Precht KS, et al. An optimized set of human telomere clones for studying telomere integrity and architecture. Am J Hum Genet 2000;67:320-32.
30. Hupe P, Stransky N, Thiery JP, Radvanyi F, Barillot E. Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics 2004;20:3413-22.
31. Freier K, Joos S, Flechtenmacher C, et al. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res 2003;63:1179-82.
32. Neben K, Korshunov A, Benner A, et al. Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 2004;64:3103-11.
33. Tibshirani R, Hastie T, Narasimhan B, Chu G. Class prediction by nearest shrunken centroids, with applications to DNA microarrays. Stat Sci 2003;18:104-17.
34. Fan J, Li R. Variable selection for Cox's proportional hazards model and frailty model. Ann Stat 2001;0:1-26.
35. Hastie T, Tibshirani R. Efficient quadratic regularization for expression arrays. Biostatistics 2004;5:329-40.
36. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
37. Debily MA, Camarca A, Ciullo M, et al. Expression and molecular characterization of alternative transcripts of the ARHGEF5/TIM oncogene specific for human breast cancer. Hum Mol Genet 2004;13:323-34.
38. Miller GJ, Miller HL, van Bokhoven A, et al. Aberrant HOXC expression accompanies the malignant phenotype in human prostate. Cancer Res 2003;63:5879-88.
39. Gimm O, Chi H, Dahia PL, et al. Somatic mutation and germline variants of MINPP1, a phosphatase gene located in proximity to PTEN on 10q23.3, in follicular thyroid carcinomas. J Clin Endocrinol Metab 2001;86:1801-5.
40. Chen HM, Schmeichel KL, Mian IS, Lelievre S, Petersen OW, Bissell MJ. AZU-1: a candidate breast tumor suppressor and biomarker for tumor progression. Mol Biol Cell 2000;11:1357-67.
41. Katoh M. Human FOX gene family [review]. Int J Oncol 2004;25:1495-500.
42. Reardon DA, Entrekin RE, Sublett J, et al. Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma. Genes Chromosomes Cancer 1999;24:230-7.
43. Kresse SH, Berner JM, Meza-Zepeda LA, et al. Mapping and characterization of the amplicon near APOA2 in 1q23 in human sarcomas by FISH and array CGH. Mol Cancer 2005;4:39.
44. Zhang XM, Dormady SP, Chaung W, Basch RS. mVH1, a dual-specificity phosphatase whose expression is cell cycle regulated. Mamm Genome 2000;11:1154-6.
45. Bortolotto S, Chiado-Piat L, Cavalla P, Bosone I, Mauro A, Schiffer D. CDKN2A/p16 in ependymomas. J Neurooncol 2001;54:9-13.
46. Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 2002;21:674-9.
47. Korshunov A, Golanov A, Timirgaz V. Immunohistochemical markers for prognosis of ependymal neoplasms. J Neurooncol 2002;58:255-70.
48. Gilbertson RJ, Bentley L, Hernan R, et al. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res 2002;8:3054-64.
49. Kondo Y, Hollingsworth EF, Kondo S. Molecular targeting for malignant gliomas [review]. Int J Oncol 2004;24:1101-9.